PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 05: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022

PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 07: MARKET SEGMENTATION BY PROCEDURE
• Segmentation by procedure
• Comparison by procedure
• G-CSF therapy - Market size and forecast 2017-2022
• Granulocyte transfusion - Market size and forecast 2017-2022
• Antibiotic therapy - Market size and forecast 2017-2022
• Splenectomy - Market size and forecast 2017-2022
• Market opportunity by procedure

PART 08: CUSTOMER LANDSCAPE

PART 09: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Americas - Market size and forecast 2017-2022
• EMEA - Market size and forecast 2017-2022
• APAC - Market size and forecast 2017-2022
• Key leading countries
• Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges

PART 12: MARKET TRENDS
• Increase in global awareness about cancer treatments
• Technological advancements
• Strategic alliances

PART 13: VENDOR LANDSCAPE
• Overview
• Landscape disruption

PART 14: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Amgen
• Intas Pharmaceuticals
• Novartis
• Partner Therapeutics
• Teva Pharmaceuticals Industries

PART 15: APPENDIX
• List of abbreviations

• Exhibit 01: Related market
• Exhibit 02: Market characteristics
• Exhibit 03: Market segments
• Exhibit 04: Market definition - Inclusions and exclusions checklist
• Exhibit 05: Market size 2017
• Exhibit 06: Validation techniques employed for market sizing 2017
• Exhibit 07: Global - Market size and forecast 2017-2022 ($ mn)
• Exhibit 08: Global - Year-over-year growth 2018-2022 (%)
• Exhibit 09: Five forces analysis 2017
• Exhibit 10: Five forces analysis 2022
• Exhibit 11: Bargaining power of buyers
• Exhibit 12: Bargaining power of suppliers
• Exhibit 13: Threat of new entrants
• Exhibit 14: Threat of substitutes
• Exhibit 15: Threat of rivalry
• Exhibit 16: Market condition - Five forces 2017
• Exhibit 17: Procedure - Market share 2017-2022 (%)
• Exhibit 18: Comparison by procedure
• Exhibit 19: G-CSF therapy - Market size and forecast 2017-2022 ($ mn)
• Exhibit 20: G-CSF therapy - Year-over-year growth 2018-2022 (%)
• Exhibit 21: Granulocyte transfusion - Market size and forecast 2017-2022 ($ mn)
• Exhibit 22: Granulocyte transfusion - Year-over-year growth 2018-2022 (%)
• Exhibit 23: Antibiotic therapy - Market size and forecast 2017-2022 ($ mn)
• Exhibit 24: Antibiotic therapy - Year-over-year growth 2018-2022 (%)
• Exhibit 25: Splenectomy - Market size and forecast 2017-2022 ($ mn)
• Exhibit 26: Splenectomy - Year-over-year growth 2018-2022 (%)
• Exhibit 27: Market opportunity by procedure
• Exhibit 28: Customer landscape
• Exhibit 29: Global - Market share by geography 2017-2022 (%)
• Exhibit 30: Regional comparison
• Exhibit 31: Americas - Market size and forecast 2017-2022 ($ mn)
• Exhibit 32: Americas - Year-over-year growth 2018-2022 (%)
• Exhibit 33: EMEA - Market size and forecast 2017-2022 ($ mn)
• Exhibit 34: EMEA - Year-over-year growth 2018-2022 (%)
• Exhibit 35: APAC - Market size and forecast 2017-2022 ($ mn)
• Exhibit 36: APAC - Year-over-year growth 2018-2022 (%)
• Exhibit 37: Key leading countries
• Exhibit 38: Market opportunity
• Exhibit 39: R&D funding for cancer for FY2013 to FY2016 ($ millions)
• Exhibit 40: Vendor landscape
• Exhibit 41: Landscape disruption
• Exhibit 42: Vendor classification
• Exhibit 43: Market positioning of vendors
• Exhibit 44: Amgen overview
• Exhibit 45: Amgen - Business segments
• Exhibit 46: Amgen - Organizational developments
• Exhibit 47: Amgen - Geographic focus
• Exhibit 48: Amgen - Key offerings
• Exhibit 49: Intas Pharmaceuticals overview
• Exhibit 50: Intas Pharmaceuticals - Business segments
• Exhibit 51: Intas Pharmaceuticals - Organizational developments
• Exhibit 52: Intas Pharmaceuticals - Geographic focus
• Exhibit 53: Intas Pharmaceuticals - Segment focus
• Exhibit 54: Intas Pharmaceuticals - Key offerings
• Exhibit 55: Novartis overview
• Exhibit 56: Novartis - Business segments
• Exhibit 57: Novartis - Organizational developments
• Exhibit 58: Novartis - Geographic focus
• Exhibit 59: Novartis - Segment focus
• Exhibit 60: Novartis - Key offerings
• Exhibit 61: Partner Therapeutics overview
• Exhibit 62: Partner Therapeutics - Business segments
• Exhibit 63: Partner Therapeutics - Organizational developments
• Exhibit 64: Partner Therapeutics - Geographic focus
• Exhibit 65: Partner Therapeutics - Key offerings
• Exhibit 66: Teva Pharmaceuticals Industries overview
• Exhibit 67: Teva Pharmaceuticals Industries - Business segments
• Exhibit 68: Teva Pharmaceuticals Industries - Organizational developments
• Exhibit 69: Teva Pharmaceuticals Industries - Geographic focus
• Exhibit 70: Teva Pharmaceuticals Industries - Segment focus
• Exhibit 71: Teva Pharmaceuticals Industries - Key offerings

Companies Mentioned
• Amgen
• Intas Pharmaceuticals
• Novartis
• Partner Therapeutics
• Teva Pharmaceuticals Industries